Business
US Patent Grant for Therapeutic Compound, VAL201
US Patent Grant for Therapeutic Compound, VAL201.
About this update from Valirx Plc
[{"type":"text","content":"\n \nRNS Number : 2012I ValiRx PLC 20 March 2018 \n\n \n \n \nVALIRX PLC\n(\"ValiRx\", the \"Company\" or the \"Group\")\n \nUS PATENT GRANT\nFOR THERAPEUTIC COMPOUND, VAL201\n \nLondon, UK., 20 March 2018: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, is pleased to announce that the United States of America patent and trademark office has granted the US Patent Application No. 14/575065 (\"Anti-Androgen Peptides and Uses Thereof in Cancer Therapy\") covering ValiRx's lead therapeutic compound, VAL201, which is in clinical trials. This follows the Company's earlier announcement on 11 January 2018, regarding its receipt of a US Patent Notice of Allowance.\n \nThe patent application covers the molecule and use of compounds in pharmaceutically acceptable products. The patent coverage also includes a wide variety of derivatives, modifications and analogues of the compounds and their mode of action. Furthermore, the protection sought includes therapeutic formulations with associated delivery systems.\n \nThe grant of this US patent for VAL201 represents one of the cornerstones of the Company's commercial strategy, since ValiRx has already secured patent protection in several other territories, including Europe. This positioning, in having patent protection in major markets, is in line with the pharmaceutical industry's increasing search for novel proprietary therapies in the oncology arena.\n \nThe table below provides details of patents in the VAL201 portfolio that have been either fully granted or allowed. \n \n\n\n\n\nCountry\n\n\nPatent number\n\n\nDate Filed\n\n\nGranted/Allowed\n\n\n\n\nUnited States\n\n\nUS 14/575065\n\n\n14 March 2008\n\n\nGranted \n\n\n\n\nEurope\n\n\nEP 08717866.1\n\n\n14 March 2008\n\n\nAllowed\n\n\n\n\nJapan\n\n\nJP 2009-553162\n\n\n14 March 2008\n\n\nGranted\n\n\n\n\nAustralia\n\n\nAU 2008228274\n\n\n14 March 2008\n\n\nGranted\n\n\n\n\nUnited Kingdom\n\n\nGB 1118831.5\n\n\n01 November 2011\n\n\nGranted\n\n\n\n\nThere are patent applications currently pending in many other territories and covering various aspects of the programme.\n\n\n\n\n \nAs announced on 18 December 2017, the compound is currently in a Phase I/II study primarily assessing safety and tolerability of VAL201 and its effect in the treatment of pros...